证券代码：600930 证券简称：华电新能 公告编号：2025-006 华电新能源集团股份有限公司 公司监事会认为：公司本次使用行使超额配售选择权对应的募集资金置换预先投入募投项目的自筹资 金，提高了募集资金使用效率，符合全体股东利益。上述事项内容及审议程序符合《上海证券交易所股 票上市规则》《上海证券交易所上市公司自律监管指引第1号一一规范运作》等相关法律法规的有关规 定，不影响募集资金投资项目的正常进行，不存在变相改变募集资金用途和损害股东利益的情形。公司 监事会同意公司使用行使超额配售选择权对应的募集资金235,252.84万元置换预先投入募投项目的自筹 资金。 表决情况：3票同意、0票反对、0票弃权。 特此公告。 一、 监事会会议召开情况 2025年8月18日，华电新能源集团股份有限公司（以下简称"公司"）第一届监事会第十二次会议以通讯 方式举行。本次会议通知于2025年8月15日以通讯方式向全体监事发出。本次会议应出席监事3名，亲自 出席监事3名，会议由邵福生主席主持。本次会议的召开符合《公司法》《公司章程》等法规及规范性 文件的有关规定。 二、监事会会议审议情况 本次会议经与会监事充分审议并有效表 ...

中信建投证券股份有限公司 关于安徽芯动联科微系统股份有限公司 使用自有资金支付募投项目所需资金并以募集资金等额置换的 核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"、"保荐人"）为 安徽芯动联科微系统股份有限公司（以下简称"芯动联科"、"公司"）首次 公开发行股票并在科创板上市的保荐人及持续督导机构，根据《证券发行上市保 荐业务管理办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票 上市规则》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》 等法规的有关规定，对芯动联科使用自有资金支付募投项目所需资金并以募集资金 等额置换事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意安徽芯动联科微系统股份有 限公司首次公开发行股票注册的批复》（证监许可[2023]1012号）同意，安徽 芯动联科微系统股份有限公司（以下简称"公司"）首次向社会公开发行人民 币普通股（A股）5,521万股。公司每股发行价格26.74元，新股发行募集资金总 额为147,631.54万元，扣除发行费用12,195.64万元后，募集资金净额135,435.90 ...

Core Viewpoint - The company, Shanghai Hehui Optoelectronics Co., Ltd., is utilizing its own funds to pay for part of the fundraising investment projects and will subsequently replace these with equivalent amounts from the raised funds, ensuring compliance with relevant regulations and maintaining operational efficiency [1][6]. Summary of Fundraising Situation - The company was approved to publicly issue shares, with a total of 3,083,660,725 shares issued at a price of 2.65 RMB per share, resulting in a net fundraising amount of approximately 8 billion RMB [1]. - As of June 30, 2025, the total committed investment for the sixth-generation AMOLED production line expansion project is approximately 800 million RMB, with cumulative investment amounting to about 663 million RMB [2]. Fundraising Investment Project Process - The company will initially use its own funds to pay for overseas equipment and services due to restrictions on the fundraising account, and will later replace these with raised funds [2][4]. - The finance department will track payments made with its own funds and will compile monthly summaries to ensure compliance with the company's fundraising management regulations [2][4]. Impact on Daily Operations - The approach of using own funds for project payments is expected to enhance fund utilization efficiency and will not affect the normal operation of fundraising investment projects or harm the interests of the company and its shareholders [4]. Decision-Making Procedures - The company’s board and supervisory committee approved the use of own funds for project payments and subsequent replacement with raised funds, ensuring compliance with legal and regulatory requirements [5]. Supervisory Committee Opinion - The supervisory committee agrees that the use of own funds followed by replacement with raised funds aligns with relevant regulations and does not alter the purpose of the raised funds or harm shareholder interests [5][6]. Sponsor Institution's Verification Opinion - The sponsor institution confirms that the company has followed necessary procedures and that the use of own funds for project payments will not disrupt the normal progress of fundraising investment projects [6].

Meeting Overview - The third meeting of the board of directors of Jiangsu Aidi Pharmaceutical Group Co., Ltd. was held on August 14, 2025, with all 7 directors present, complying with relevant regulations [1]. Agenda Items - The board approved the adjustment of the 2025 stock option incentive plan, reducing the number of incentive recipients from 45 to 43 and the total stock options from 9.1 million to 8.96 million due to the departure of 2 recipients [1][2]. - The board agreed to grant stock options to the 2025 incentive recipients, with the grant date set for August 14, 2025, and a total of 8.96 million stock options to be issued at an exercise price of 13.01 yuan per share [2][3]. - The board approved the use of self-owned funds and bank acceptance bills to finance fundraising projects, which will be replaced by the raised funds, enhancing fund efficiency and reducing costs [3][4].

Core Viewpoint - Zhejiang Meilun Elevator Co., Ltd. has made significant decisions regarding the use of raised funds, including replacing self-raised funds and managing idle funds, which are expected to enhance financial efficiency and shareholder returns [2][3][5][7]. Fund Management - The company plans to use raised funds to replace self-raised funds amounting to RMB 75.27 million and issuance expenses of RMB 1.86 million, totaling RMB 77.13 million [2][3][6]. - The replacement of funds will occur within six months of the funds being received [3][6]. - The company intends to manage idle raised funds of up to RMB 150 million for cash management, ensuring it does not affect the normal investment plans [7][8]. Capital Changes - The company has approved a change in registered capital from RMB 307 million to RMB 349.05 million following a stock issuance of 42,049,469 shares at a price of RMB 5.66 per share [4][6]. - The updated capital structure will be reflected in the company's articles of association, which will be revised accordingly [4][6]. Financial Performance - As of August 5, 2025, Meilun Elevator's stock closed at RMB 9.01, marking a 3.8% increase with a trading volume of 139,100 lots and a turnover of RMB 123 million [1][2]. - The net inflow of main funds on that day was RMB 16.31 million, accounting for 13.27% of the total turnover [2][5].

Core Viewpoint - The company intends to use its own funds to pay for part of the investment project and subsequently replace it with raised funds, which is in compliance with regulatory requirements and aims to enhance the efficiency of fund utilization [1][5]. Fundraising Basic Situation - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds, with net fundraising amounting to approximately 253.43 million yuan after deducting related expenses [1][2]. Investment Project Basic Situation - As of June 30, 2025, the total investment for the projects, including the Jiangsu Phase II, Hubei Pharmaceutical Sorting and Processing Center, and Hebei Pharmaceutical Warehouse, amounts to 253.43 million yuan, with 179.74 million yuan allocated from the raised funds [2]. Reasons for Using Own Funds - The company faces challenges in using raised funds directly for certain expenses, such as employee salaries and social insurance, which must be paid through the basic deposit account. Therefore, it plans to use up to 7.05 million yuan of its own funds for these payments and later replace them with raised funds [3][4]. Impact on the Company - The use of self-funds for project payments and subsequent replacement with raised funds is expected to improve fund utilization efficiency and ensure the smooth progress of investment projects without affecting the normal implementation of the projects [4][5]. Review Procedures and Opinions - The company's board and supervisory committee have approved the proposal to use self-funds for the investment project, confirming that this action does not harm the interests of the company or its shareholders and complies with relevant regulations [5].

Core Viewpoint - Beijing Yitang Semiconductor Technology Co., Ltd. plans to use raised funds amounting to CNY 2,097,556,497.48 to replace self-raised funds previously invested in fundraising projects and paid issuance expenses, in compliance with relevant regulations and within six months of the funds being received [1][5][7] Summary of Fundraising Situation - The company raised a total of CNY 2,342,867,334.94 through its initial public offering (IPO) of 295,560,000 shares at a price of CNY 8.45 per share, as confirmed by KPMG Huazhen [1][2] - The raised funds are managed in a dedicated account, with a tripartite supervision agreement signed with the sponsor and the bank [1] Summary of Investment Projects - The net amount raised is lower than the initially disclosed amount in the prospectus, leading to adjustments in the investment amounts for the fundraising projects [2] - The adjusted investment amounts for the projects are as follows: - Yitang Semiconductor Integrated Circuit Equipment R&D Manufacturing Service Center: CNY 250,000,000 - Yitang Semiconductor High-end Integrated Circuit Equipment R&D Project: CNY 234,286,730 - Total adjusted investment: CNY 234,286,730 [2] Summary of Self-raised Funds and Replacement Arrangement - The actual investment amount from self-raised funds prior to the IPO was CNY 2,042,867,334.94, which the company plans to replace with the raised funds [4][6] - The total amount for replacing self-raised funds and issuance expenses is CNY 2,097,556,497.48, which includes CNY 54,689,162.54 for issuance expenses [4][5] Review Procedures - The board and supervisory committee approved the proposal to use raised funds for replacement on July 25, 2025, confirming compliance with regulatory requirements [4][6][7] - The supervisory committee and KPMG Huazhen provided opinions supporting the replacement, affirming that it does not affect the normal progress of fundraising projects or harm shareholder interests [6][7]

Summary of Key Points Core Viewpoint - The company, Jiangsu Xiangteng New Materials Co., Ltd., has received approval to use its own funds to pay for part of the fundraising investment projects and will subsequently replace these with equivalent amounts from the raised funds, ensuring compliance with relevant regulations and maintaining project efficiency [1][7]. Group 1: Fundraising Overview - The company issued 17,171,722 shares at a price of RMB 28.93 per share, raising a total of RMB 496.78 million, with a net amount of RMB 464.49 million after deducting underwriting and other fees [1][2]. - The company has established a special account for the raised funds and signed a tripartite supervision agreement with the bank and the sponsor [2]. Group 2: Investment Project Details - The total investment for the projects is RMB 501.76 million, with an actual planned use of raised funds amounting to RMB 442.34 million [3]. Group 3: Reasons for Using Own Funds - The company faced challenges in directly using raised funds for payroll and other expenses due to regulatory requirements, necessitating the use of its own funds initially [4][5]. - Payments for social insurance, housing funds, and taxes must be made through a unified bank account, complicating the use of multiple accounts for raised funds [4]. - The need for foreign currency payments for overseas purchases and customs duties further limited the use of the raised funds account [5]. Group 4: Operational Process for Fund Replacement - The company plans to use its own funds for project payments and will replace these with raised funds within six months, following a defined approval and replacement process [6]. - The financial department will manage the replacement process, ensuring compliance with the established procedures [6]. Group 5: Impact on the Company - The use of own funds for project payments is aligned with regulatory requirements and is expected to enhance fund utilization efficiency without affecting the normal implementation of the projects [6][7]. Group 6: Approval Process - The board of directors and the supervisory board approved the proposal to use own funds for project payments on July 24, 2025, without needing shareholder approval [6]. Group 7: Sponsor's Verification Opinion - The sponsor, Everbright Securities, confirmed that the decision-making process was followed correctly and that the use of own funds for project payments complies with relevant laws and regulations [7].

Group 1 - The core point of the announcement is the approval by the Supervisory Board of China General Nuclear Power Corporation to use funds raised from convertible bonds to replace self-raised funds already invested in projects and to cover issuance costs [1][2] - The meeting was held on July 14, 2025, and the proposal received unanimous approval with 5 votes in favor and no votes against or abstaining [1] - The Supervisory Board believes that the use of raised funds aligns with the company's development needs and will enhance capital utilization efficiency, complying with relevant regulations from the China Securities Regulatory Commission and Shenzhen Stock Exchange [1]

Core Viewpoint - China General Nuclear Power Corporation (CGN) is issuing convertible bonds to replace self-raised funds previously invested in projects and to cover issuance costs, with a total fundraising amount of RMB 490 million [7][10]. Group 1: Company Responsibilities - The company is responsible for preparing the special explanation regarding the replacement of self-raised funds with the proceeds from the convertible bonds, ensuring the information is true, accurate, and complete [2][11]. - The preparation of the special explanation is in accordance with the regulations set by the China Securities Regulatory Commission (CSRC) and the Shenzhen Stock Exchange [8][11]. Group 2: Fundraising Details - The company plans to issue 49 million convertible bonds with a face value of RMB 100 each, resulting in a total fundraising amount of RMB 490 million, after deducting issuance costs of RMB 2.1581 million [7][10]. - The net amount raised after costs is RMB 489.78419 million, which has been deposited into a designated account [7][10]. Group 3: Use of Proceeds - The net proceeds from the bond issuance will be used for specific investment projects as outlined in the fundraising plan [9][10]. - Prior to the bond proceeds being available, the company has already invested RMB 972.43963 million of its own funds into the projects from June 22, 2024, to July 14, 2025, with RMB 489.78419 million planned for replacement [10]. Group 4: Issuance Costs - The company has incurred issuance costs totaling RMB 0.2968 million, with a net amount of RMB 0.2685 million planned for replacement using the bond proceeds [10]. - The breakdown of issuance costs includes underwriting fees, legal fees, audit fees, and other related expenses [10]. Group 5: Verification and Conclusion - KPMG Huazhen LLP has conducted a verification of the fundraising and issued a report confirming that the special explanation reflects the situation accurately as of July 14, 2025 [6][11]. - The company asserts that the information disclosed complies with the relevant regulations and accurately reflects the use of self-raised funds [11].